Primary Outcome Measures:
- Average of Subjective Sleep Latency [ Time Frame: Days -14, 1, 30, 60, 90, 120, 150, 180 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Average of Total Sleep Time (TST) and Wake Time After Sleep Onset (WASO) [ Time Frame: Days -14, 1, 30, 60, 90, 120, 150, 180 ] [ Designated as safety issue: No ]
- SF-36 [ Time Frame: Days 1, 30, 90, 180 ] [ Designated as safety issue: No ]
- Work Limitations Questionnaire (WLQ) [ Time Frame: Days 1, 30, 90, 180 ] [ Designated as safety issue: No ]
- Insomnia Severity Index (ISI) [ Time Frame: Days 1, 30, 90, 180 ] [ Designated as safety issue: No ]
- Fatigue Severity Scale (FSS) [ Time Frame: Days 1, 30, 90, 180 ] [ Designated as safety issue: No ]
- Epworth Sleepiness Scale (ESS) [ Time Frame: Days 1, 30, 60, 90, 120, 150, 180 ] [ Designated as safety issue: No ]
- Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) [ Time Frame: Day 180 ] [ Designated as safety issue: No ]
- Healthcare Utilization Questionnaire (HUQ) [ Time Frame: Days 1, 30, 60, 90, 120, 150, 180 ] [ Designated as safety issue: No ]
This is a double blind, randomized (2:1; eszopiclone : placebo), placebo-controlled, multicenter, study of eszopiclone in subjects with primary insomnia. The study will involve up to 9 visits and subject participation will be approximately 224 days. After meeting all screening criteria, subjects will be randomized to either eszopiclone 3 mg QD or placebo.